IonQ Option Alert: Feb 28 $34.5 Calls Sweep (22) near the Bid: 1537 vs 124 OI; Earnings 2/26 After Close 

IonQ Option Alert: Feb 28 $34.5 Calls Sweep (22) near the Bid: 1537 @ $3.697 vs 124 OI; Earnings 2/26 After Close Ref=$34.17

IonQ (NYSE:IONQ) 주식

IONQ INC

IonQ

IonQ Inc sells access to several quantum computers of various qubit capacities and is in the process of researching and developing technologies for quantum computers with increasing computational capabilities. The company currently makes access to its quantum computers available via cloud platforms and also to select customers via its own cloud service. This cloud-based approach enables the broad availability of quantum-computing-as-a-service (QCaaS). The company derives its revenue from its quantum-computing-as-a-service arrangements, consulting services related to co-developing algorithms on company's quantum computing systems and contracts associated with the design, development, and construction of specialized quantum computing systems together with related services.

D-Wave Quantum Inc.

Equities

Mid Cap

News

Movers

Trading Ideas

HSAI

IONQ

ORLA

PTGX

QBTS

RGTI

SMTC

이 중형주들은 지난주에 가장 좋은 성과를 냈습니다. 당신의 포트폴리오에 있나요? 1. D-웨이브 퀀텀(NYSE:QBTS)의 주식은 회사가 4분기 수주가 1억 8,300만 달러로 전년 대비 502% 증가했다고 보고한 후 95.95% 상승했다.

D-웨이브 퀀텀과 아이온큐 등 지난주 급등한 중형주 8종목 (3월 10일-3월 14일)

stock_whisper_index_logo_6_copy

Exclusives

$SUI

FWONA

FWONK

매주, 벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 받을 만한 주식 5종목을 소개한다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 스프라우츠, 아이온큐, 닥터 페퍼, 선 커뮤니티즈 및 포뮬러 원

Quantum Computing Stock QUBT Has More Than Doubled While Bitcoin Has Dropped Since Google’s ‘Willow’ Reveal: What Does This Mean?

Long Ideas

Tech

Interview

MSFT

NVDA

엔비디아(NASDAQ:NVDA)의 CEO 젠슨 황은 GPU에 모든 것을 걸고 있지만, 아이온큐(NYSE:IONQ)의 CEO 니콜로 데 마시(Niccolo De Masi)는 양자 컴퓨팅이 다음 큰 일이라고 주장하며 물러서지 않고 있다.

아이온큐 CEO, 엔비디아의 젠슨 황에 반박하여 &#34;우리는 여전히 800파운드의 게릴라이다&#34;

IonQ Inc

IonQ, Inc. Redeemable warrants, each whole warrant exercisable for one share of Common Stock, each at an exercise price of $11.50 per share

<p><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.mirion.com%2Fabout%2Fmirion-technologies&amp;esheet=54231430&amp;newsitemid=20250401641022&amp;lan=en-US&amp;anchor=Mirion+Technologies&amp;index=1&amp;md5=92eaf322ade9bfa9dc58e215863498fe">Mirion Technologies</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MIR#NYSE">MIR</a>), a global provider of advanced radiation safety solutions, today announced the latest release of its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.mirion.com%2Fproducts%2Ftechnologies%2Fspectroscopy-scientific-analysis%2Fgamma-spectroscopy%2Fgamma-spectroscopy-software%2Flab-applications%2Fapex-guard-lab-productivity-suite&amp;esheet=54231430&amp;newsitemid=20250401641022&amp;lan=en-US&amp;anchor=Apex-Guard+gamma+spectroscopy+software&amp;index=2&amp;md5=cf34c438266ce7b41c571e637559c2d4">Apex-Guard gamma spectroscopy software</a>. Tailored to meet the stringent regulatory demands of commercial radioisotope producers, Apex-Guard software V1.2 significantly enhances the Mirion solutions suite within the radiopharmaceutical supply chain with a robust impurity analysis for radioisotope producers. This software release reinforces the Mirion commitment to improving quality in cancer care, through focused innovation across its Mirion Technologies and Mirion Medical groups.</p>
<p>The radiopharmaceutical field is experiencing rapid expansion, with over 100 drugs currently in Phase I or further clinical development stages1 poised to revolutionize patient-centric diagnosis and treatment in cancer care and other medical specialties. To manage the growth, radioisotope producers require robust quality management and impurity analysis to ensure compliance and patient safety.</p>
<p>Building on the established Mirion Technologies Genie&#x2122; and Apex-Gamma&#x2122; gamma spectroscopy software platforms, Apex-Guard software offers advanced controls, security, audit features, and data integrity. These features support compliance with regulations such as U.S. FDA 21 CFR Part 112. The latest version introduces a solution for Radionuclidic purity gamma spectroscopy measurements through a broadly applicable, ready-to-use patent-pending algorithm. This advancement streamlines quality management processes, increases confidence in quality and facilitates efficient regulatory compliance.</p>
<p>Apex-Guard software further enhances the radiopharmaceutical lifecycle through streamlined workflows via interoperability with industry-leader BioTrax QMS&#xAE;, an electronic quality management tool encompassing inventory management, document management, and production batch records from ec2 Software, a Mirion Medical Company.</p>
<p>"Mirion is deeply committed to providing the most advanced and reliable technologies for the radiopharmaceutical field, which plays a critical role in modern cancer care," said Tom Logan, Mirion CEO. "The rapid growth in the radiopharmaceutical sector has increased demand for radioisotopes used in cancer care. This new Apex-Guard release demonstrates our investment in aiding the acceleration of these life-changing advancements in precision medicine by ensuring the highest quality and safety standards."</p>
<p>&nbsp;</p>


Biotech

General

Mirion Technologies Releases Its Latest Apex-Guard Gamma Spectroscopy Software

<p>The <strong>Bob Fireman Award for Entrepreneurship</strong> will once again take center stage at the <strong><a href="https://www.benzinga.com/cannabis-conference">2025 Benzinga Cannabis Capital Conference</a></strong>, which is taking place <strong><a href="https://www.benzinga.com/cannabis-conference">June 8-10 at the Chicago Marriott Downtown Magnificent Mile</a>.</strong> <a href="https://forms.gle/QiC6dwFxKx3thTAV6">Nominations</a> are now officially open, with the winner to be announced during the event. The deadline to submit nominations is May 1st, 2025. You can nominate your favorite cannabis leader <a href="https://forms.gle/QiC6dwFxKx3thTAV6">here</a>.</p>
<h2 class="wp-block-heading">What&#8217;s The Bob Fireman Award?</h2>
<p>This award was created to honor the legacy of Robert "Bob" Fireman, the late co-founder and CEO of MariMed, who passed away in December 2022. A trailblazer in the legal cannabis industry, Fireman entered the space in 2008 alongside his best friend and current MariMed CEO, <strong>Jon Levine</strong>. Together, they built a company rooted in trust, compassion and a belief in the power of cannabis to improve lives.</p>
<p>Each year, the Bob Fireman Award for Entrepreneurship recognizes a cannabis executive who embodies Bob's spirit of integrity, leadership and community commitment. The recipient must reflect the same values that guided Fireman's life and career:</p>
<ul>
<li>Doing what you say you'll do</li>
<li>Building a company culture of trust, collaboration, hard work and fun</li>
<li>Serving as an outstanding representative of the cannabis community</li>
</ul>
<h3 class="wp-block-heading">Loriel Alegrete: 2024 Honoree</h3>
<p>In 2024, the award was presented to <strong>Loriel Alegrete,</strong> CEO and co-founder of <strong>40 Tons,</strong> a cannabis brand that merges entrepreneurship with social justice. Under Alegrete's leadership, 40 Tons has become a symbol of ethical business and community impact, focusing on restorative justice, job placement, and opportunities for individuals affected by the War on Drugs.</p>
<p>By highlighting cannabis as a force for change, Alegrete brought national attention to the need for equity in an evolving industry. Her commitment to education, advocacy and workforce development captured the essence of what the Bob Fireman Award is all about.</p>
<h3 class="wp-block-heading">Recognizing The Next Cannabis Visionary</h3>
<p>As the cannabis space matures, the award seeks to elevate those who not only build businesses but also shape the culture and direction of the industry. Leaders who challenge norms, elevate others and lead with heart are encouraged to apply—or be nominated by their peers.</p>
<p>To <a href="https://forms.gle/QiC6dwFxKx3thTAV6">submit a nomination</a> for the 2025 Bob Fireman Award, <a href="https://forms.gle/QiC6dwFxKx3thTAV6">follow this link</a> and complete the form before the May 1st deadline. The winner will be announced live at the conference during a special ceremony.</p>
<p>For those planning to attend, <a href="https://www.benzinga.com/cannabis-conference">the conference</a> will feature more than 120 speakers from across the cannabis ecosystem, as well as unique networking opportunities and investor connections. <a href="https://www.benzinga.com/cannabis-conference">Tickets are available now</a>, including general admission and VIP options.</p>
<p>As Jon Levine said during last year's ceremony, "Bob always worked hard as a business leader, attorney, and advocate for our industry. He guided MariMed to deliver on our mission to improve people's lives through cannabis." The award in his name is a call to continue that mission—and to honor those who do.</p>


Cannabis

Events

Know A Cannabis Leader Who Stands Out? Nominations Now Open For Bob Fireman Award By Benzinga

<p>Ncino (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.19 by 36.84 percent. This is a 42.86 percent decrease over earnings of $0.21 per share from the same period last year.  The company reported quarterly sales of $141.370 million which beat the analyst consensus estimate of $140.841 million by 0.38 percent.  This is a 14.29 percent increase over sales of $123.693 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

NCNO

Ncino Q4 2025 Adj. EPS $0.12 Misses $0.19 Estimate, Sales $141.370M Beat $140.841M Estimate

LINE

Lineage Acquires Bellingham Cold Storage; Financial Terms Not Disclosed

Management

INBX

Inhibrx Biosciences Announces Departure Of Dr. Brendan Eckelman, Co-founder And Chief Scientific Officer And Appoints Dr. Carlos Bais And David Matly to CSO and President, Respectively

<p>The Amendment, which became effective March 31, 2025, adjusts certain financial covenants to support the Company's evolving business model as it progresses through its strategic transformation. Among other items, the Amendment reduces the level of Crop and Tree Insurance coverage requirements required for the 2025/2026 harvest season, which is expected to result in cost savings for Alico.</p>


ALCO

Alico Announces Amendment To Credit Agreement Supporting Transformation

Buybacks

nCino Plans Stock Repurchase Program For Up To $100M Of Outstanding Common Stock

Bank OZK Declares Quarterly Cash Dividend On The Bank's Common Stock Of $0.43 per share, Up 2.38% From The Prior Quarter

ALGN

Align Reports Commercial Availability Of Invisalign System With Mandibular Advancement Featuring Occlusal Blocks For Class II Skeletal And Dental Correction

Offerings

BOLD

Boundless Bio Files For Mixed Shelf Of Up To $400M

<ul>
<li>Multi-year strategic partnership enhances on-device video and video conferencing experiences</li>
<li>Brings computer vision-based AI to life and delivers powerful video conferencing and content creation experiences for a hybrid workforce on next-gen AI PCs</li>
<li>AI capabilities run on-device for low-latency, private, secure, and offline usage experiences on the NPU<br /><br />&nbsp;</li>
</ul>
<p>PALO ALTO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Reincubate – an innovator in edge AI and audio-video processing – and HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) announced today that they have formed a strategic multi-year partnership to build upon Reincubate's industry-leading AI video conferencing technology to enhance on-device video and video conferencing experiences.</p>
<p>"We're excited to partner with Reincubate to harness its AI video technology, enabling HP's next gen AI PC users to collaborate clearly," said Guayente Sanmartin, Senior Vice President &amp; Division President, Commercial Systems &amp; Display Solutions at HP. "This partnership leverages HP's next-gen AI PC NPUs to deliver more immersive digital collaboration experiences. Because all the AI processing of video and audio is entirely local on the NPU, it's not only more efficient, but completely secure."</p>
<p><strong>Equipping best-in-class AI PCs with tools that make the most of NPUs</strong></p>
<p>Neural-processing units, or NPUs, in AI PCs unleash the next generation of capabilities in notebooks, allowing for private, secure, and always-connected experiences that use minimal CPU and GPU resources, enabling higher performance and longer-lasting battery life. Reincubate's AI capabilities are optimized for NPU-equipped SoCs (system on a chip) from HP's silicon partners.</p>
<p>"We're thrilled to be partnering with HP to deliver powerful new experiences to nurture creativity, making personal systems more personal for modern work environments and consumers. With its leading position, HP is the ideal partner to extend the reach of our technology. HP's remarkable innovation in technology, design, and AI is a fine counterpart to our work," said Reincubate CEO Aidan Fitzpatrick. "I'm excited to contribute to HP's leadership by helping create more authentic, higher quality video experiences for its customers."</p>
<p><strong>About Reincubate</strong></p>
<p>Reincubate makes Camo, the popular app that gives users video superpowers. Reincubate's patented technology harnesses digital video and audio devices, enabling users to improve, customise and personalise the video they meet, present, stream or record with. Reincubate's capabilities leverage AI, run natively on multiple platforms, and are optimised for NPU. Reincubate is based in London, UK. For more information, please visit: reincubate.com.</p>


Contracts

HP and Reincubate Enter Partnership To Deliver Personalized, NPU-Based, On-Device AI Capabilities

Government

Regulations

Asset Sales

ORCL

Trump Will Consider A Final Proposal For Tiktok Tomorrow; Trump Admin Is Finalizing Plans For Potential Investors That Could Include Blackstone And Oracle

<p>Analysts' ratings for Astrana Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTH#NASDAQ">ASTH</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $47.83, a high estimate of $56.00, and a low estimate of $36.00. A 25.27% drop is evident in the current average compared to the previous average price target of $64.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743537743_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Astrana Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$36.00</td>
<td>-</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$46.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Adam Ron</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$49.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Craig Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$56.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$59.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Astrana Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Astrana Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Astrana Health's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Astrana Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ASTH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Astrana Health analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Astrana Health</h2>
<p>Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.</p>
<h3>Financial Milestones: Astrana Health's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Astrana Health's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>88.43%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Astrana Health's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-1.04%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-0.98%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Astrana Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-0.53%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.66</strong>, Astrana Health adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

ASTH

Assessing Astrana Health: Insights From 6 Financial Analysts

<p>Alloush Will Continue To Also Serve As The Company's General Counsel.</p>


DERM

Journey Medical Promotes Ramsey Alloush, Currently General Counsel, To The Position Of COO

<p>Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $396.57, a high estimate of $423.00, and a low estimate of $355.00. This current average represents a 4.86% decrease from the previous average price target of $416.83. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743537735_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A clear picture of Sherwin-Williams's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$355.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Laurence Alexander</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$380.00</td>
<td>$423.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$423.00</td>
<td>-</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$390.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$415.00</td>
<td>$438.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$408.00</td>
<td>$435.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Sherwin-Williams. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sherwin-Williams compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Sherwin-Williams's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Sherwin-Williams's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SHW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Sherwin-Williams analyst ratings.</strong></a></p>
<h2>Discovering Sherwin-Williams: A Closer Look</h2>
<p>Sherwin-Williams is the largest provider of architectural paint in the United States. The company has over 5,000 stores and sells premium paint at higher price points than most competitors. Sherwin-Williams also sells paint-related products in big-box stores and provides coatings for original equipment manufacturers.</p>
<h3>A Deep Dive into Sherwin-Williams's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Sherwin-Williams's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>0.86%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Materials sector.</p>
<p><strong>Net Margin:</strong> Sherwin-Williams's net margin is impressive, surpassing industry averages. With a net margin of <strong>9.06%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>11.7%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Sherwin-Williams's ROA excels beyond industry benchmarks, reaching <strong>2.02%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Sherwin-Williams's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>2.94</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About Sherwin-Williams Stock

<p>Throughout the last three months, 6 analysts have evaluated Advanced Drainage Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMS#NYSE">WMS</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $148.83, with a high estimate of $160.00 and a low estimate of $134.00. A decline of 6.54% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743537727_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of Advanced Drainage Systems by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collin Verron</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$134.00</td>
<td>-</td>
</tr>
<tr>
<td>Garik Shmois</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$160.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$149.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Trey Grooms</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>John Lovallo</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$155.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Advanced Drainage Systems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Advanced Drainage Systems compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Advanced Drainage Systems's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into Advanced Drainage Systems's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/WMS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Advanced Drainage Systems analyst ratings.</strong></a></p>
<h2>Get to Know Advanced Drainage Systems Better</h2>
<p>Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe; Infiltrator; International and Allied Products and Other. It generates maximum revenue from the Pipe segment. The company serves Agriculture; Aviation and Military; Mining; Residential; Transportation; Healthcare and Education and others.</p>
<h3>A Deep Dive into Advanced Drainage Systems's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Advanced Drainage Systems's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>4.25%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> Advanced Drainage Systems's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>11.76%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Advanced Drainage Systems's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>5.38%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Advanced Drainage Systems's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>2.28%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Advanced Drainage Systems's debt-to-equity ratio is below the industry average. With a ratio of <b>0.91</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 6 Analyst Projections For Advanced Drainage Systems

<p>Goldman Sachs Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">11</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $661.93, along with a high estimate of $782.00 and a low estimate of $550.00. This current average has increased by 0.15% from the previous average price target of $660.92. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743537713_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Goldman Sachs Group by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$594.00</td>
<td>$660.00</td>
</tr>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$680.00</td>
<td>$720.00</td>
</tr>
<tr>
<td>Kian Abouhossein</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$625.00</td>
<td>$605.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$550.00</td>
<td>$585.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$659.00</td>
<td>$782.00</td>
</tr>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$720.00</td>
<td>$680.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$640.00</td>
<td>$610.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$760.00</td>
<td>$713.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$782.00</td>
<td>$736.00</td>
</tr>
<tr>
<td>David Konrad</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$690.00</td>
<td>$686.00</td>
</tr>
<tr>
<td>Kian Abouhossein</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$605.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$713.00</td>
<td>$588.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$610.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$639.00</td>
<td>$677.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Goldman Sachs Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Goldman Sachs Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>To gain a panoramic view of Goldman Sachs Group's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Goldman Sachs Group analyst ratings.</strong></a></p>
<h2>Delving into Goldman Sachs Group's Background</h2>
<p>Goldman Sachs is a leading global investment banking and asset management firm. Approximately 14% of its revenue comes from investment banking, 42% from trading, 20% from asset &amp; wealth management, 15% from net interest income, and 9% from other principal transactions. Around 64% of the company's net revenue is generated in the Americas, 13% in Asia, and 23% in Europe, the Middle East, and Africa.</p>
<h3>Breaking Down Goldman Sachs Group's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> Goldman Sachs Group's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>22.54%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Goldman Sachs Group's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>28.29%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Goldman Sachs Group's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>3.62%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Goldman Sachs Group's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.23%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Goldman Sachs Group's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>3.15</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing Goldman Sachs Group: Insights From 14 Financial Analysts

<p>Deep-pocketed investors have adopted a bullish approach towards KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in KLAC usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for KLA. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 60% leaning bullish and 30% bearish. Among these notable options, 5 are puts, totaling $241,300, and 5 are calls, amounting to $223,340.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $600.0 and $750.0 for KLA, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for KLA's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across KLA's significant trades, within a strike price range of $600.0 to $750.0, over the past month.</p>
<h3>KLA 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743537701_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>KLAC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$104.5</td>
<td>$101.6</td>
<td>$102.2</td>
<td>$700.00</td>
<td>$71.5K</td>
<td align="right">4</td>
<td align="right">12</td>
</tr>
<tr>
<td>KLAC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$65.9</td>
<td>$64.6</td>
<td>$64.6</td>
<td>$710.00</td>
<td>$64.6K</td>
<td align="right">108</td>
<td align="right">0</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$23.4</td>
<td>$22.6</td>
<td>$23.4</td>
<td>$750.00</td>
<td>$56.1K</td>
<td align="right">217</td>
<td align="right">24</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$23.9</td>
<td>$23.9</td>
<td>$23.9</td>
<td>$740.00</td>
<td>$52.5K</td>
<td align="right">45</td>
<td align="right">22</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$46.5</td>
<td>$41.0</td>
<td>$45.0</td>
<td>$670.00</td>
<td>$45.0K</td>
<td align="right">1</td>
<td align="right">10</td>
</tr>
</tbody>
</table>
</p>
<h3>About KLA</h3>
<p>KLA is one of the largest semiconductor wafer fabrication equipment, or WFE, manufacturers in the world. It specializes in the market segment of semiconductor process control, wherein machines inspect semiconductor wafers during research and development and manufacturing for defects and verify precise measurements. In this section of the market, KLA holds a majority share. It also has a small exposure to the etch and deposition segments of the WFE market. It counts as top customers the largest chipmakers in the world, including TSMC and Samsung.</p>
<p>Following our analysis of the options activities associated with KLA, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is KLA Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 388,008, with KLAC's price down by -0.26%, positioned at $678.04.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 23 days.</li>
</ul>
<h3>Professional Analyst Ratings for KLA</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $797.5.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; In a positive move, an analyst from Morgan Stanley has upgraded their rating to Overweight and adjusted the price target to $870.<br />
&#x2A; An analyst from Jefferies downgraded its action to Hold with a price target of $725. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for KLA, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

KLAC

KLA Options Trading: A Deep Dive into Market Sentiment

Sterling Bancorp Chairman, CEO And President Thomas O'Brien Steps Down; Steven E. Gallotta Appointed Chairman

<p>Ratings for United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $123.0, along with a high estimate of $140.00 and a low estimate of $80.00. A decline of 3.23% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743537700_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of United Airlines Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sheila Kahyaoglu</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$107.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Andrew Didora</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Christopher Stathoulopoulos</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Ravi Shanker</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Savanthi Syth</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jamie Baker</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$133.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Christopher Stathoulopoulos</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$120.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$139.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to United Airlines Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of United Airlines Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of United Airlines Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into United Airlines Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/UAL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on United Airlines Holdings analyst ratings.</strong></a></p>
<h2>All You Need to Know About United Airlines Holdings</h2>
<p>United Airlines is a major us network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel than its large us peers.</p>
<h3>United Airlines Holdings: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, United Airlines Holdings showcased positive performance, achieving a revenue growth rate of <strong>7.85%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> United Airlines Holdings's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>6.7%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> United Airlines Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>8.16%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> United Airlines Holdings's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.34%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>2.65</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


10 Analysts Assess United Airlines Holdings: What You Need To Know

Press Releases

IonQ Joins SXSW 2025's Expanded Quantum Programming Lineup

Quantum Computing Stocks Tumble Amid Industry Skepticism

IonQ Raises Over $372 Million Via At-the-Market Equity Offering Program

IonQ Expands Quantum Networking Patent Portfolio to Meet Strong Market Demand for Secure Communications

Defiance Launches IONX: 2X Leveraged ETF for IonQ

Small Cap

Opinion

Quantum Computing Just Took Another Giant Leap--What It Means for Investors

IonQ Executive Chair Joins Panel with NVIDIA CEO to Discuss Quantum at NVIDIA's First-Ever Quantum Day

IonQ and Ansys Achieve Major Quantum Computing Milestone – Demonstrating Quantum Outperforming Classical Computing

GraniteShares 2x Long IONQ Daily ETF (IONL), GraniteShares 2x Long VRT Daily ETF (VRTL), and GraniteShares 2x Long RDDT Daily ETF (RDTL) Launch Today.

IonQ Announces Global Availability of Forte Enterprise Through Amazon Braket and IonQ Quantum Cloud

CSE:SCPE

IONL

QMCO

QUBT

RDDT

RDTL

RGTIW

SCPCF

VRTL

Apple

AstroNova

Canaan

CompoSecure

Corsair Gaming

Diebold Nixdorf Incorporated Common stock

Diebold Nixdorf

Dell Technologies Inc. Class C Common Stock

Dell Technologies

Foxx Development Holdings Inc. - Common Stock

Foxx Development Hldgs

Hewlett Packard Enterprise Company Common Stock

Hewlett Packard

Immersion

Eastman Kodak

Movano

NetApp

One Stop Systems

CPI Card

Pure Storage

Quantum

Super Micro Computer, Inc. - Common Stock

Super Micro Computer

SanDisk

Seagate Technology Holdings PLC - Ordinary Shares (Ireland)

Seagate Tech Hldgs

TransAct Technologies Incorporated - Common Stock

Transact Technologies

Turtle Beach

Western Digital Corporation - Common Stock

Western Digital

Xerox Holdings Corporation - Common Stock

Xerox Holdings

Benchmark

Needham

Goldman Sachs

Craig-Hallum

DA Davidson

WIIM

IonQ shares are trading higher after the company made its flagship quantum computer, IonQ Forte Enterprise, available to global customers through Amazon Braket and the IonQ Quantum Cloud.

Comments

IonQ

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌